Prostate Cancer - Results from #180

Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI. December 3, 2021

Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial. December 3, 2021

Patient- and Surgeon-Level Variation in Patient-Reported Sexual Function Outcomes Following Radical Prostatectomy Over 2 Years: Results From a Statewide Surgical Improvement Collaborativep. December 3, 2021

Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting. December 3, 2021

Genetics of prostate cancer and its utility in treatment and screening. December 2, 2021

Application of Artificial Intelligence to Overcome Clinical Information Overload in Urologic Cancer. December 2, 2021

Is tumour volume an independent predictor of outcome after radical prostatectomy for high-risk prostate cancer? December 2, 2021

Urinary incontinence and use of incontinence surgery after radical prostatectomy: a national study using patient-reported outcomes. December 2, 2021

Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. December 2, 2021

Primary staging in patients with intermediate- and high-risk prostate cancer: Multiparametric MRI and 68Ga-PSMA-PET/MRI - What is the value of quantitative data from multiparametric MRI alone or in conjunction with clinical information? December 1, 2021

Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer. December 1, 2021

Shared Medical Appointments for Prostate Cancer Active Surveillance Follow-Up Visits. December 1, 2021

A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer. December 1, 2021

177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. December 1, 2021

Movember Launches Global Bid to Reduce the Risk of Prostate Cancer Progression November 30, 2021

Sociodemographic and Geographic Disparities of Prostate Cancer Treatment Delay in Tennessee: A Population-Based Study. November 30, 2021

Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients. November 30, 2021

A prospective study on inter-operator variability in semi-robotic software-based MRI/TRUS-fusion targeted prostate biopsies. November 30, 2021

Four-year Prostate-specific Antigen Response Rate as a Predictive Measure in Intermediate-risk Prostate Cancer Treated With Ablative Therapies: The SPRAT Analysis. November 30, 2021

PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial. November 30, 2021

Page 10 of 1199

email news signup